NuCana (NASDAQ:NCNA) Trading Down 2.4% – Time to Sell?

NuCana PLC Sponsored ADR (NASDAQ:NCNA) shares were down 2.4% during trading on Thursday . The company traded as low as $1.60 and last traded at $1.60. 26,135 shares were traded during trading, a decline of 46% from the average daily volume of 48,707 shares. The stock had previously closed at $1.64.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of NuCana in a research note on Tuesday, April 21st. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock currently has an average rating of “Sell”.

NuCana Stock Down 2.4%

The stock has a market cap of $6.66 million, a P/E ratio of -0.54 and a beta of 2.18. The stock has a fifty day simple moving average of $2.03 and a 200-day simple moving average of $2.41.

NuCana (NASDAQ:NCNA) last announced its quarterly earnings results on Friday, May 15th. The company reported ($1.25) EPS for the quarter, beating analysts’ consensus estimates of ($2.64) by $1.39.

Institutional Investors Weigh In On NuCana

A hedge fund recently raised its position in NuCana stock. FNY Investment Advisers LLC grew its position in NuCana PLC Sponsored ADR (NASDAQ:NCNA) by 210.0% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 10,000 shares of the company’s stock after purchasing an additional 6,774 shares during the period. FNY Investment Advisers LLC owned about 33.33% of NuCana worth $36,000 at the end of the most recent reporting period. Institutional investors own 44.00% of the company’s stock.

NuCana Company Profile

NuCana plc, headquartered in Edinburgh, Scotland, is a clinical-stage biopharmaceutical company focused on developing novel anti-cancer therapies. The company leverages its proprietary ProTide platform to deliver enhanced nucleoside analogues designed to overcome resistance mechanisms commonly encountered in standard chemotherapy regimens. NuCana’s research and development efforts are aimed at improving safety and efficacy profiles for patients with a range of solid tumor indications.

At the core of NuCana’s pipeline is NUC-3373, a next-generation fluoropyrimidine analogue engineered to bypass degradation pathways and achieve more consistent intracellular exposure.